Article Type

Original Study


Panobinostat is a new histone deacetylaseinhibitor approved fortreatmentof advanced multiple myeloma.In this study we compare itseffectswith doxorubicin which is alreadyused for trans-arterial chemoembolizationof hepatocellular carcinoma. Methods: anti-proliferativeand pro-apoptotic effects of panobinostatand doxorubicin are tested bymeasuringcell viability, P53, pd1 expressionand cell cycle analysis inHepG2cells cultured in suitable mediaand incubated with both drugs for24hours. Results:Panobinostat wasfoundto highly significantly induce apoptosis via increasing expressionof both P53 and pd1 and decreasecell viability and mitosis more thandoxorubicin. Conclusion: These resultssuggest that panobinostat maybea potent alternative to doxorubicinfortreatment of hepatocellular carcinoma.

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.